A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Clinical trial NCT06393712 · RECRUITING

Trial details

NCT number: NCT06393712
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cerebral Amyloid Angiopathy

Start date: 2024-05-17
Primary completion: 2027-08-09
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.